A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis

Brief description of study

The purpose of this research study is to see how safe the study drug, EXE-346, is after 4 weeks of treatment in patients with high bowel movement frequency who have undergone ileal pouch-anal anastomosis (IPAA) after colon removal (partial or full removal).

This study will last about 10 weeks and will involve about 5 visits. While in this study you will be asked to record your bowel movement frequency, take the study drug 2 times a day, and complete the in person and over the phone safety follow-ups.

Clinical Study Identifier: s23-01258
Principal Investigator: Shannon Chang.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.